Eli Lilly and Company (NYSE:LLY) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 9.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,816 shares of the company's stock after selling 3,491 shares during the quarter. Eli Lilly and Company accounts for 0.9% of B. Riley Wealth Advisors Inc.'s portfolio, making the stock its 13th biggest holding. B. Riley Wealth Advisors Inc.'s holdings in Eli Lilly and Company were worth $26,106,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. Brick & Kyle Associates purchased a new position in Eli Lilly and Company in the 4th quarter valued at about $2,087,000. Armis Advisers LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth $583,000. Chokshi & Queen Wealth Advisors Inc acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth $741,000. Garde Capital Inc. raised its position in shares of Eli Lilly and Company by 22.7% in the 4th quarter. Garde Capital Inc. now owns 1,107 shares of the company's stock worth $855,000 after buying an additional 205 shares during the period. Finally, Wilkins Miller Wealth Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at $421,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Up 1.5%

NYSE:LLY traded up $11.03 during mid-day trading on Tuesday, reaching $724.74. The stock had a trading volume of 3,786,668 shares, compared to its average volume of 3,623,076. The stock's 50 day simple moving average is $786.82 and its two-hundred day simple moving average is $802.40. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a market capitalization of $686.86 billion, a price-to-earnings ratio of 61.89, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the business earned $2.58 earnings per share. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. Eli Lilly and Company's payout ratio is currently 48.82%.

Analysts Set New Price Targets

A number of research firms have recently commented on LLY. Truist Financial raised their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their target price for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.